Ind-Swift Laboratories Ltd
Pharmaceuticals & Biotechnology | Small Cap
Ind-Swift Laboratories exhibits a mixed financial profile. Profitability stands out as a key strength, driven by healthy margins and returns on capital. Solvency is also strong, indicating a low reliance on debt. Liquidity shows potential, supported by current and quick ratios, but is offset by a low operating cash flow ratio. However, the company has faced major issues in growth and inefficieny. Capital expenditure is low which is affecting company's growth. Overall, Ind-Swift Laboratories demonstrates solid profitability and solvency, but needs to address issues in growth and financial management to achieve a more balanced and robust financial performance.
Latest Report
View AllLatest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsNeutral
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio2.00
- Financial Ratio2.40
- Profitability Ratio9.80
- Efficiency Ratio4.67
- Coverage Ratio5.60
- Solvency Ratio9.00
- Liquidity Ratio6.98
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentBalanced
- 1 HourBullish
- 2 HoursBullish
- 4 HoursBullish
- 1 DayStrong Bullish
- 1 WeekBullish
- 1 MonthBullish
Ind-Swift Laboratories exhibits a mixed financial profile. Profitability stands out as a key strength, driven by healthy margins and returns on capital. Solvency is also strong, indicating a low reliance on debt. Liquidity shows potential, supported by current and quick ratios, but is offset by a low operating cash flow ratio. However, the company has faced major issues in growth and inefficieny. Capital expenditure is low which is affecting company's growth. Overall, Ind-Swift Laboratories demonstrates solid profitability and solvency, but needs to address issues in growth and financial management to achieve a more balanced and robust financial performance.
Latest Report
View AllLatest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
Overall Valuation Score
P/E RATIO (TTM)
38.32
Industry Median
28.62
Small Cap Median
27.17
P/E RATIO
39.28
P/B RATIO
1.18
Industry Median
3.17
Small Cap Median
2.62
P/S RATIO
2.55
Industry Median
3.42
Small Cap Median
2.55
Others
PEG RATIO
0.00
EV/EBITDA RATIO
15.06
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹187.38 as on Jun 19, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
Quarterly Report⬤31st Jan 26
Quarterly Financial Results Q3 FY 2025-26
NEUTRAL SENTIMENT
The company is witnessing negative growth in revenue, operating profit, EPS, assets and net income. Revenue and operating profit growth have declined, reflecting challenges in expanding sales and maintaining profitability. A decline in asset growth indicates reduced investment in new opportunities or contraction of business activities. This could be due to various factors, including market conditions, competition, or internal inefficiencies.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 16.61 | 16.17 | 41.59 | -67.12 | 14.06 |
| Operating Profit Growth Rate | 10.38 | 13.37 | 33.62 | -106.21 | -336.84 |
| Earnings Per Share (EPS) Growth | -32.08 | -2338.89 | 1031.27 | -54.68 | -88.46 |
| Asset Growth Rate | -0.94 | 1.28 | -19.96 | -1.51 | 16.34 |
| Net Income Growth Rate | -33.33 | -2500 | 1022.92 | -53.62 | -83.6 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The company's financial metrics present a mixed picture. Both adjusted and cash earnings per share are low, indicating limited profitability relative to share value. The book value per share is also low, suggesting a modest net asset value for each share. High capital expenditures may reflect investments in growth initiatives, but this should translate to future earnings.
| Financial Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 0.17 | 10.33 | 22.39 | 0.14 | 5.63 |
| Cash Earnings Per Share (Cash EPS) | 21.5 | 17.5 | 92.39 | 39.71 | 8.28 |
| Book Value Per Share | 100.17 | 113.67 | 121.19 | 170 | 159.08 |
| Dividend Per Share (DPS) | 0 | 0 | 0 | 0 | 0 |
| Capital Expenditures (CapEx) | 12 | 13 | 63 | 25 | 87 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The company exhibits strong profitability, reflected in high gross profit, ROCE, ROE, ROA, operating margin, and net margin. High return on capital employed and return on equity indicate efficient use of capital and equity to generate profits. Strong profitability can enhance investor confidence and support future growth initiatives. This suggest that the company is making enough profits.
| Profitability Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Profit Margin | 6.83 | 14.25 | 13.22 | -7.65 | 2.18 |
| Return on Capital Employed (ROCE) | 7 | 13 | 21 | 1 | 5 |
| Return on Equity (ROE) | -0.33 | 7.04 | 66.38 | 21.31 | 2.96 |
| Return on Assets (ROA) | 11.22 | 12.55 | 20.96 | -1.32 | 2.69 |
| Operating Margin | 19.44 | 18.97 | 17.91 | -3.38 | 7.02 |
| Net Margin | -0.19 | 3.98 | 31.54 | 44.48 | 6.4 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The company's efficiency in managing its assets is mixed. The company demonstrates strong efficiency in utilizing its fixed assets, which contributes positively to overall performance. However, low inventory and receivable turnover ratios and the capital turnover ratio indicate areas where asset management could be improved, potentially leading to better operational efficiency. Also, company's days sales in inventory and receivable days are average.
| Efficiency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 1.65 | 2.06 | 8.9 | 2.06 | 2.09 |
| Inventory Turnover Ratio | 2.41 | 2.39 | 5.77 | 6.4 | 4.79 |
| Receivables Turnover Ratio | 2.34 | 2.51 | 4.18 | 2.35 | 3.52 |
| Days Sales in Inventory Ratio | 151.45 | 152.72 | 63.26 | 57.03 | 76.2 |
| Receivable Days | 155.98 | 145.42 | 87.32 | 155.32 | 103.69 |
| Capital Turnover Ratio | 0.72 | 0.84 | 1.71 | 0.47 | 0.46 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
The company's ability to cover its interest expenses is good. However, the company does not have enough equity dividend coverage ratio. This can affect investor sentiments.
| Coverage Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | 1.14 | 1.95 | 6.75 | 87 | 50 |
| Equity Dividend Coverage Ratio |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The company's solvency position is strong, evident by its low debt and debt to asset ratio. A conservative approach to financial leverage can provide stability, especially in an industry with fluctuating revenues. A higher equity ratio further supports this stability, indicating a strong capital base.
| Solvency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debt Ratio | 0.59 | 0.52 | 0.2 | 0.02 | 0.01 |
| Debt to Equity Ratio | 1.44 | 1.08 | 0.25 | 0.02 | 0.01 |
| Equity Ratio | 0.41 | 0.48 | 0.8 | 0.98 | 0.99 |
| Debt To Asset Ratio | 0.47 | 0.41 | 0.14 | 0.02 | 0.01 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The company shows adequate ability to meet its short-term obligations, evident from its Current and Quick ratios. However, the company's cash ratio is moderate, suggesting potential challenges in meeting immediate liabilities with only cash and cash equivalents. Also, the company's operating cash flow is negative which is concerning.
| Liquidity Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Current Ratio | 3.22 | 3.08 | 2.46 | 3.98 | 4.01 |
| Quick Ratio | 2 | 1.95 | 2.29 | 3.51 | 3.48 |
| Cash Ratio | 0.06 | 0.05 | 1.1 | 1.79 | 1.55 |
| Operating Cash Flow Ratio | 0.43 | 0.5 | -0.42 | -0.1 | -0.25 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Accent Microcell Ltd | 7.96 | 24.25 | Neutral | 57.00 | 18.28 | 44.00 |
| 2 | Lincoln Pharmaceuticals Ltd | 7.31 | 14.01 | Neutral | 98.00 | 43.88 | 88.00 |
| 3 | NGL Fine Chem Ltd | 6.98 | 39.22 | Overvalued | 73.00 | 67.39 | 48.00 |
| 4 | Medico Remedies Ltd | 6.61 | 37.70 | Overvalued | 17.00 | 1.58 | 13.00 |
| 5 | Kilitch Drugs (India) Ltd | 6.61 | 21.54 | Neutral | 37.00 | 9.27 | 30.00 |
| 6 | Kopran Ltd | 6.60 | 25.82 | Neutral | 62.00 | 6.30 | 26.00 |
| 7 | SMS Lifesciences India Ltd | 6.59 | 21.20 | Undervalued | 45.00 | 70.68 | 19.00 |
| 8 | Infinium Pharmachem Ltd | 6.42 | 26.90 | Neutral | 22.00 | 6.43 | 14.00 |
| 9 | Sakar Healthcare Ltd | 5.81 | 58.66 | Highly Overvalued | 69.00 | 13.70 | 30.00 |
| 10 | Medicamen Biotech Ltd | 5.73 | 32.19 | Neutral | 20.00 | 6.94 | 10.00 |
| 11 | Albert David Ltd | 5.63 | -272.47 | Neutral | 5.00 | -2.62 | -1.00 |
| 12 | Zim Laboratories Ltd | 5.41 | 41.96 | Neutral | 30.00 | 1.11 | 6.00 |
| 13 | Remus Pharmaceuticals Ltd | 5.31 | 25.48 | Neutral | 57.00 | 20.97 | 46.00 |
| 14 | Ind-Swift Laboratories Ltd | 4.95 | 39.28 | Neutral | 45.00 | 4.89 | 41.00 |
| 15 | Venus Remedies Ltd | 4.83 | 23.37 | Neutral | 147.00 | 74.30 | 103.00 |
| 16 | Wanbury Ltd | 4.65 | 28.62 | Neutral | 88.00 | 18.93 | 43.00 |
| 17 | Nectar Lifescience Ltd | 3.83 | -2.67 | Neutral | -59.00 | -2.95 | -293.00 |
The management of Ind-Swift Laboratories exhibits a mixed performance. The company has demonstrated strong profit growth and a remarkable reduction in debt. However, inconsistent sales growth and recent declines in quarterly results raise concerns. The promoter holding is stable, and institutional interest has fluctuated. Overall, the management's effectiveness is rated as mixed due to strengths in financial management offset by weaknesses in sales consistency.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Compounded Profit Growth (3Y) | 260% | Strong profit growth |
| Debt Reduction | Borrowings reduced from ₹1,240 Cr in 2013 to ₹17 Cr in 2024 | Significant debt reduction | |
| CONS | Recent Sales Decline | YOY Sales Growth % (Dec 2024): -97% | Declining sales growth |
| Recent OPM Decline | OPM % (Dec 2024): -167.90% | Declining operating profit margin |
Financial Performance & Growth
Ind-Swift Laboratories demonstrates mixed financial growth. While profit growth has been strong, sales growth has been inconsistent, with a recent sharp decline. The recent quarterly results showing significant declines in both sales and operating profit margin highlight potential challenges in maintaining consistent financial performance.
| Metric | 2014-2016 | 2017-2019 | 2020-2022 | 2023 | 2024 | |---|---|---|---|---|---|---| | Sales Growth % | -15.87% | 5.93% | 15.73% | 16.23% | 6.10% | | Operating Profit | 81.67 | 122 | 134.33 | 229 | 252 |
Capital Efficiency & Returns
The company's capital efficiency and returns present a positive picture. ROCE and ROE are strong, indicating effective use of capital and shareholder funds.
| Metric | Value |
|---|---|
| ROCE | 55.54 |
| ROE | 59.20 |
Financial Health & Prudence
Ind-Swift Laboratories has shown significant improvement in its financial health. The company has substantially reduced its borrowings, leading to a stronger balance sheet.
| Metric | 2013-2015 | 2016-2018 | 2019-2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Average Borrowings | 1369 | 1262 | 1028.67 | 953 | 862 | 17 |
Shareholding & Ownership Structure
The shareholding pattern of Ind-Swift Laboratories indicates a stable promoter holding, fluctuating institutional interest, and a significant public holding. The promoter holding is consistent. The increase in public holding and simultaneous decrease in DII holding raise concerns about long-term institutional confidence. The fluctuations in FII holdings indicate varying levels of interest from foreign investors.
| Metric | Jun 2022 | Mar 2023 | Jun 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Promoters | 42.00% | 42.01% | 42.01% | 42.01% | 40.94% |
| FIIs | 0.00% | 0.00% | 1.27% | 0.46% | 3.07% |
| DIIs | 19.49% | 19.49% | 0.94% | 0.94% | 0.91% |
| Public | 38.50% | 38.52% | 55.81% | 56.61% | 55.08% |
The risk assessment for Ind-Swift Laboratories reveals a mixed situation. While the company has significantly reduced its debt, improving its financial stability, there are concerns regarding recent performance volatility, particularly in sales and profitability. The company's high cash conversion cycle indicates potential inefficiencies in working capital management, and the significant foreign exchange exposure due to international operations adds to the risk profile.
Segment performance volatility
The quarterly results show significant volatility in sales and profitability. YOY Sales Growth % varies widely, and OPM % fluctuates dramatically, including negative values. This indicates inconsistent performance and potential instability in the company's operations.
| Metric | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| YOY Sales Growth % | 9% | 35% | 12% | 32% | 27% | -1% | 11% | -7% | -8% | 29% | -89% | -96% | -97% |
| OPM % | 21.24% | 11.97% | 18.92% | 18.94% | 17.19% | 20.93% | 19.43% | 22.67% | 17.98% | 19.45% | -29.36% | -98.66% | -167.90% |
Foreign exchange or interest rate exposure
The company's operations involve international sales, creating a foreign exchange exposure risk. Fluctuations in exchange rates can significantly impact revenue and profitability. The presence of international sales indicates that the company is subject to foreign exchange risks.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
- IndicatorValueSignal
- SMA 10176.69Bullish
- SMA 20170.80Bullish
- SMA 50165.13Bullish
- EMA 10178.44Bullish
- EMA 20173.29Bullish
- EMA 50167.26Bullish
- DEMA 10185.08Bullish
- DEMA 20180.13Bullish
- DEMA 50173.63Bullish
- TEMA 10187.68Bullish
- TEMA 20184.02Bullish
- TEMA 50175.79Bullish
- MACD5.63Bullish
- ADX49.38Strong Trend
- IndicatorValueSignal
- RSI85.45Overbought
- CCI188.52Overbought
- ROC 913.04Bullish
- ROC 1416.53Bullish
- ROC 2515.08Bullish
- Stoch K96.86Overbought
- Stoch D90.80Overbought
- IndicatorValueSignal
- BB Upper186.57Overbought
- BB Middle170.80Neutral
- BB Lower155.03Neutral
- ATR3.67High Volatility
- IndicatorValueSignal
- MFI93.67Overbought
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
- IndicatorValueSignal
- SMA 10172.56Bullish
- SMA 20167.48Bullish
- SMA 50163.10Bullish
- EMA 10175.40Bullish
- EMA 20170.25Bullish
- EMA 50163.41Bullish
- DEMA 10182.62Bullish
- DEMA 20176.77Bullish
- DEMA 50172.23Bullish
- TEMA 10186.36Bullish
- TEMA 20180.34Bullish
- TEMA 50174.49Bullish
- MACD5.51Bullish
- ADX41.81Strong Trend
- IndicatorValueSignal
- RSI84.15Overbought
- CCI247.82Overbought
- ROC 916.46Bullish
- ROC 1415.71Bullish
- ROC 2518.96Bullish
- Stoch K90.90Overbought
- Stoch D88.05Overbought
- IndicatorValueSignal
- BB Upper183.67Overbought
- BB Middle167.48Neutral
- BB Lower151.29Neutral
- ATR4.42Low Volatility
- IndicatorValueSignal
- MFI95.82Overbought
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
- IndicatorValueSignal
- SMA 10167.63Bullish
- SMA 20164.73Bullish
- SMA 50152.34Bullish
- EMA 10170.48Bullish
- EMA 20165.46Bullish
- EMA 50156.55Bullish
- DEMA 10176.79Bullish
- DEMA 20173.19Bullish
- DEMA 50166.61Bullish
- TEMA 10180.13Bullish
- TEMA 20174.97Bullish
- TEMA 50N/AN/A
- MACD6.03Bullish
- ADX52.42Strong Trend
- IndicatorValueSignal
- RSI78.26Overbought
- CCI344.89Overbought
- ROC 917.93Bullish
- ROC 1416.25Bullish
- ROC 2519.60Bullish
- Stoch K87.00Overbought
- Stoch D77.85Neutral
- IndicatorValueSignal
- BB Upper178.52Overbought
- BB Middle164.73Neutral
- BB Lower150.94Neutral
- ATR6.40High Volatility
- IndicatorValueSignal
- MFI85.06Overbought
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Market Sentiment
Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
- IndicatorValueSignal
- SMA 10161.68Bullish
- SMA 20153.96Bullish
- SMA 50144.94Bullish
- SMA 100138.93Bullish
- SMA 200119.10Bullish
- EMA 10161.30Bullish
- EMA 20155.94Bullish
- EMA 50147.18Bullish
- EMA 100137.75Bullish
- EMA 200126.04Bullish
- DEMA 10166.58Bullish
- DEMA 20164.51Bullish
- DEMA 50157.88Bullish
- DEMA 100153.84Bullish
- DEMA 200142.01Bullish
- TEMA 10166.45Bullish
- TEMA 20167.80Bullish
- TEMA 50160.10Bullish
- TEMA 100158.89Bullish
- TEMA 200152.89Bullish
- MACD6.58Bullish
- ADX27.18Strong Trend
- IndicatorValueSignal
- RSI68.64Neutral
- CCI83.24Neutral
- ROC 1410.89Bullish
- ROC 2522.13Bullish
- Stoch K73.51Neutral
- Stoch D73.42Neutral
- IndicatorValueSignal
- BB Upper177.98Neutral
- BB Middle153.96Neutral
- BB Lower129.95Neutral
- ATR7.95High Volatility
- IndicatorValueSignal
- MFI81.03Overbought
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 20139.27Bullish
- SMA 50116.40Bullish
- EMA 20136.94Bullish
- EMA 50122.53Bullish
- DEMA 20151.06Bullish
- DEMA 50136.59Bullish
- TEMA 20154.70Bullish
- TEMA 50146.32Bullish
- MACD10.69Bullish
- ADX33.08Strong Trend
- IndicatorValueSignal
- RSI68.68Neutral
- CCI164.56Overbought
- ROC 1419.14Bullish
- ROC 2574.53Bullish
- Stoch K73.36Neutral
- Stoch D55.58Neutral
- IndicatorValueSignal
- BB Upper159.53Overbought
- BB Middle139.27Neutral
- BB Lower119.00Neutral
- ATR15.31High Volatility
- IndicatorValueSignal
- MFI66.36Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
- IndicatorValueSignal
- SMA 6128.00Bullish
- SMA 12114.68Bullish
- SMA 24112.73Bullish
- EMA 6131.99Bullish
- EMA 12120.64Bullish
- EMA 24111.47Bullish
- DEMA 6146.31Bullish
- DEMA 12133.81Bullish
- DEMA 24124.69Bullish
- TEMA 6151.47Bullish
- TEMA 12142.80Bullish
- TEMA 24127.82Bullish
- MACD14.72Bullish
- ADX29.32Strong Trend
- IndicatorValueSignal
- RSI58.61Neutral
- CCI159.05Overbought
- ROC 2527.13Bullish
- ROC 50128.22Bullish
- Stoch K35.79Neutral
- Stoch D33.16Neutral
- IndicatorValueSignal
- BB Upper149.05Overbought
- BB Middle106.58Neutral
- BB Lower64.12Neutral
- ATR25.95High Volatility
- IndicatorValueSignal
- MFI89.73Overbought